Klin Onkol 2004; 17(5): 167-171.
Summary:
Purpose: Paclitaxel and cisplatin are active in treatment of advanced cervical cancer and both potentiate the effects of radiotherapy. In our study we evaluated the therapeutical effect and toxicity of these radiosensitizers administered weekly in concomitance with standard radiotherapy. Methods: Between October 1999 and June 2003, sixty patients with locoregionally advanced cervical cancer stage IIB-IIIB were treated with radiotherapy and concomitant chemotherapy. Paclitaxel at 50mg/m2 in group I (30 patients) versus cisplatin at 40 mg/m2 in group II (30 patients) were administered once a week. The chemotherapy continued until irradiation (conventional external and intracavitary) completion.
Results: There were no significant differences between group I and II in DFI (P=0,66) and OS (P=0,60). Median follow up was 18 months versus 12 months, CR 90% versus 80% in group I and II, respectively. Leukopenia gr. 2 or 3 (P=0,038), GIT toxicity (P<0,001) and urological toxicity (P=0,035) were detected. Alopecia and hypersensitivity were detected only in group I. Toxicities were mild with no treatment related deaths. No significant differences in DFI were detected between various histological types.
Conclusions: Our study demonstrated high efficacy of both radiosensitizers with no significant differences in DFI and OS between paclitaxel and cisplatin. Chemotherapy was well tolerated and toxicities were mild.
